Filter Results
Filter Results
Allogeneic (38) Autologous (44) Bioconjugates/ADC (17) Exosomes (17) Expression Technologies (88) iPSCs (31) Mammalian (102) Microbial (21) mRNA (16) Parenteral Drug Product (33) Small Molecules (188) Viral Vectors (50)
Antibody Drug Conjugates (30) Bioavailability Enhancement (81) Bispecific Antibody (74) Difficult to Express Proteins (53) Drug device combinations (1) Drug Substance (API/HPAPI) (69) Enhanced ADCC (13) Fabs, Fusion, Scaffold and other Recombinant Proteins (31) Inhalation (35) Injectables (6) Lipid Nanoparticle Encapsulation (5) Monoclonal Antibody (74) Oral Drug Products (91) Particle Engineering (50) Solid Form Services (13)
Analytical Development (56) Antibody Humanization & Deimmunization (5) API Services (38) Bispecific DNA-to-IND (14) Cell Line Development (68) Clinical Supply Services (54) Commercial Supply Services (39) Early De-risking & Optimization (41) Fabs and Fc-Fusion proteins DNA-to-IND (2) First-in-Human Services (55) Formulation Development and Optimization (87) Ibex® Dedicate (3) Immunogenicity Assessment (11) IND-to-BLA (18) mAb DNA-to-IND: Ibex® Design (12) Manufacturing: cGMP (54) Manufacturing: GMP Drug Product (20) Manufacturing: GMP Drug Substance (38) Manufacturing: Non-GMP Manufacture (4) Parenteral Drug Product Development (12) PBPK Modeling (11) Process Development and Optimization (81) Regulatory Services (33) Scaffolds and Other Recombinant Proteins DNA-to-IND (3) Solid Form Services (6) Special Analytical Services (2) Strain Development (7) Tech Transfer (7) Tissue Acquisition (6) Viral Vector Expression Technologies (19)
4D-Nucleofector LV (4) bYlok™ Bispecific Antibodies Technology (16) Cocoon® Platform (26) GS Discovery® (12) GS Effex® (14) GS Gene Expression System® (52) GS piggyBac® Transposon System (47) GS Xceed® Gene Expression System (53) GSquad® Vectors (32) Hot Melt Extrusion (27) LNP (5) Mammalian Expression Technologies (67) Microbial Expression Technologies (19) Micro-dosing/Powder-in-capsule (14) Micronization (17) MODA® (5) Modified and Delayed Release (9) Particle Size Reduction (27) Spray Dried Dispersions (55) Taste-masking and Multiparticulates (12) Technology Selection (20) Viral Vector Expression Technologies (18) Xcite® (6) XS Technologies® (8)
Article (67) CDMO Notes Blog post (8) e-book (11) Interview (6) Peer-reviewed publication (35) Podcast (41) Poster (33) Presentation (on-demand) (31) Presentation (slides) (13) R&D Blog post (23) Report (1) Technical/Service brief (42) Video (19) Webinar (on-demand) (158) White paper (102)
   Loading...
Showing 1‐28 of 590
Article
5 min read
Partnering for Innovation: Lonza Supports a UK Biotech Developing an Entirely New Modality with IgE-based Cancer Immunotherapy
Epsilogen CEO, Tim Wilson, shares his company’s experience finding the right CDMO partner, willing to collaborate with a small biotech on developing and manufacturing a novel class of antibodies, IgE-based immunotherapies, designed to combat solid tumors,...
White paper
15 min read
Transferring your cell line with confidence
This white paper explores flexible, data-driven strategies that help streamline biologics development, mitigate risks, and accelerate timelines—especially when transitioning from underperforming systems or navigating fast-track regulatory pathways. W...
Article
15 min read
Q&A: Getting it right first time - the importance of early expression vector design
In this interview, Lonza’s Dr. Peter O’Callaghan (Senior Director, Head of Expression System Sciences) and Dr. Rachel Da Rosa (Product Manager, Licensing and Early Access Services), address questions on the importance of DNA vector design in determining b...
Webinar (on-demand)
53 min read
Future-proofing gene therapy: scalable AAV solutions and non-viral innovations
As gene therapy moves toward broader commercialization, the pressure to streamline production and ensure consistent, high-quality output has never been greater. Here, we explore strategies to develop simplified, scalable state-of-the-art platforms designe...
Technical/Service brief
8 min read
GS Gene Expression System: reliability today, innovation for tomorrow
Emerging and small biotechs play a critical role in driving scientific innovation, often advancing bold ideas with the potential to transform patient outcomes. At Lonza, we understand the unique challenges you face – maximizing limited resources, navigati...
Article
5 min read
The Evolving Landscape of ADC Analytical Development
White paper
10 min read
Xcite®: an optimized transient transfection platform to accelerate your AAV program from gene to GMP
Unlock the full potential of your AAV program with Xcite®: a proven path from gene to GMP by being faster, smarter, and more scalable In the race to bring gene therapies to patients, everyday counts. But for many developers, the journey from discovery ...
Webinar (on-demand)
22 min read
Amorphous Solid Dispersions (ASDs): Pre-clinical to Commercial Capabilities
Is your drug candidate struggling with solubility, slowing down its path to market? Discover how Amorphous Solid Dispersions (ASDs) can be your breakthrough solution, from early development to commercial success. ...
White paper
10 min read
Unlock key insights of end-to-end regulatory CDMO solutions
Navigating the complex world of drug development and regulatory approval just got easier. Our recent webinar, "End-to-end regulatory CDMO solutions: development, manufacturing, and approval," offered invaluable insights into streamlining your journey from...
Webinar (on-demand)
25 min read
Lonza's integrated ADC offering: From concept to commercialization
As the Antibody-Drug Conjugate (ADC) market continues its robust expansion, the demand for specialized manufacturing expertise is paramount. Lonza, a leading CDMO, offers a complete end-to-end solution that simplifies the value chain and accelerates the t...
Webinar (on-demand)
55 min read
Solving the inhalation puzzle: A CDMO's guide to dry powder development
Unlock the secrets to successful pulmonary and nasal drug delivery with our exclusive on-demand webinar: "Solving the inhalation puzzle: A CDMO's guide to dry powder development." Inhalation and nasal delivery are transforming how we deliver therape...
Webinar (on-demand)
Navigating the CMC regulatory landscape during protein medicinal product development and manufacturing
Explore the evolving regulatory landscape for protein-based therapeutics in this on-demand webinar. Gain strategic insights into Chemistry, Manufacturing, and Controls (CMC) requirements across the product lifecycle—from preclinical development to market ...
CDMO Notes Blog post
10 min read
Fit-for-purpose analytical methods to accelerate the development and manufacture of new molecular formats
Learn how Lonza's experts develop fit-for-purpose analytical methods to ensure quality, consistency, and regulatory success for complex biologics. Read more.
CDMO Notes Blog post
10 min read
Smarter expression approaches for multi-chain therapeutic protein formats
Our customers play a critical role in driving innovation, often advancing multi-chain and new therapeutic formats to transform patient outcomes. To keep pace, cutting-edge therapeutic protein expression technology is essential - boosting titers, product q...
R&D Blog post
4 min read
Monitoring residual host cell proteins in pharmaceutical products to ensure patient safety
Biologics manufacturing mostly relies on host organisms, such as Chinese hamster ovary (CHO) cells and Escherichia coli, to produce therapeutic proteins.
Podcast
2 min read
A View On Microbial Manufacturing (S04 E06)
In this episode, we hear from Karlheinz Flicker and Joan Cortada, two experts from Lonza's microbial R&D team, about the important role of microbial technology in sustainable biomanufacturing.
White paper
10 min read
Precision in miniature: optimizing multiparticulate formulations for pediatric oncology
This white paper details a collaborative effort between Lonza’s Bend, OR site and Pfizer’s Groton, CT team to develop a robust commercial control strategy for a pediatric dosage form for crizotinib (Xalkori) in a material sparing fashion. The multiparticu...
Webinar (on-demand)
50 min read
Continuous flow techniques for pharmaceutical manufacturing at Lonza
Traditional batch reactors have served us well, but what if there was a more efficient, cost-effective, and robust way to produce pharmaceuticals and fine chemicals? In this on-demand webinar, we dive into the world of continuous flow processes...
White paper
10 min read
Better, faster small-molecule synthesis: leveraging modern tools to evaluate and optimize process chemistry
Lonza’s Advanced Synthesis family of solutions for testing and optimizing synthetic processes assist drug developers in navigating the path from discovery to commercialization. As small-molecule APIs become more complex, AI-enabled route scouting, HTE, ...
Technical/Service brief
5 min read
GS Effex® Cell Line for Enhanced Antibody Effector Function
GS Effex® derived from Lonza's leading GS Xceed® cell line, has been engineered to lack the enzyme responsible for the addition of fucose, α1,6-fucosyltransferase. This industrially relevant cell line produces antibodies free of fucose with enhanced...
Technical/Service brief
1 min read
XS Technologies® Microbial Platform for Protein Expression Brochure
XS Technologies® are the microbial expression systems for today’s therapeutics. While achieving yields of up to 20 g/L for simple proteins and up to 12 g/L for more complex proteins, they merge simplicity and scalability. XS Technologies® Expression Syste...
Article
5 min read
Navigating the Future of Bioconjugates and ADCs: An Expert Q&A with Iwan Bertholjotti
Webinar (on-demand)
Fixing the Fixed: Unlocking Efficiency in Large-Scale Microbial Manufacturing
It's often assumed that bioprocesses become fixed and unchanging as they move into commercial production, constrained by the boundaries of the regulatory dossier. In reality, commercial manufacturing is anything but static. In this on-demand webinar,...
Webinar (on-demand)
60 min read
Unlock the future of drug development with PBBM and solid form screening for early-phase success
Struggling with poor bioavailability in your early-phase drug candidates? You're not alone. Low aqueous solubility is a common hurdle, delaying critical First-in-Human (FIH) trials and inflating costs. But what if you could accelerate development...
Article
10 min read
Empowering smarter decisions in drug development through modeling, AI and scientific expertise
Webinar (on-demand)
52 min read
Building Better Biologics: Early strategies for optimizing the progression of biotherapeutic candidates to first in human studies and beyond
The early stages of biologic drug development are critical to long-term clinical and commercial success. As biologics become more complex, an integrated approach to candidate selection, preclinical evaluation, and manufacturing readiness is essential. Th...
Poster
3 min read
Cocoon® platform demonstrates compatibility with off-the-shelf process analytical technologies
The Lonza Cocoon® Platform uniquely addresses the challenges of automated cell therapy manufacturing by enabling at-line integration of a variety of complementary systems such as Process Analytical Technologies (PAT) and electroporation. The integration o...
Poster
3 min read
End-to-end production of t cells on the Cocoon® platform, using buoyancy-activated cell sorting (bacs) for direct isolation from leukopaks
High-purity, viable T cell isolation is essential for consistent upstream processing of CAR-T cell manufacturing. Traditional magnetic cell separation uses positive or negative selection; the latter preserves cell integrity by avoiding activation and rece...